Hepalink Pharma's Thrombosis Medication Gets South African Marketing Approval

MT Newswires Live

Apr 25

South African authorities approved Shenzhen Hepalink Pharmaceutical's (HKG:9989, SHE:002399) sale of its ivenoxin injection, according to a Thursday filing with the Hong Kong bourse.

Ivenoxin is indicated to prevent thrombosis before and after surgery. It also helps with reducing thrombosis risk in patients with acute conditions causing movement restrictions and in hemodialysis patients.

The drug also treats deep vein thrombosis and reduces complications in unstable angina, the filing stated.

Subsidiary Shenzhen Techdow Medicine produces the injection.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2530433079"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2530433079\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2530433079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-25 10:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2530433079","market":"sh","top_or_hot":-1,"title":"Hepalink Pharma's Thrombosis Medication Gets South African Marketing Approval","media":"MT Newswires Live","content":"<html><body><p> South African authorities approved Shenzhen Hepalink Pharmaceutical's (HKG:9989, SHE:002399) sale of its ivenoxin injection, according to a Thursday filing with the Hong Kong bourse.</p><p>Ivenoxin is indicated to prevent thrombosis before and after surgery. It also helps with reducing thrombosis risk in patients with acute conditions causing movement restrictions and in hemodialysis patients.</p><p>The drug also treats deep vein thrombosis and reduces complications in unstable angina, the filing stated.</p><p>Subsidiary Shenzhen Techdow Medicine produces the injection.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hepalink Pharma's Thrombosis Medication Gets South African Marketing Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHepalink Pharma's Thrombosis Medication Gets South African Marketing Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-25 10:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> South African authorities approved Shenzhen Hepalink Pharmaceutical's (HKG:9989, SHE:002399) sale of its ivenoxin injection, according to a Thursday filing with the Hong Kong bourse.</p><p>Ivenoxin is indicated to prevent thrombosis before and after surgery. It also helps with reducing thrombosis risk in patients with acute conditions causing movement restrictions and in hemodialysis patients.</p><p>The drug also treats deep vein thrombosis and reduces complications in unstable angina, the filing stated.</p><p>Subsidiary Shenzhen Techdow Medicine produces the injection.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0070","symbol_name":"员工持股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2530433079","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2530433079","pubTimestamp":1745547489,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"South African authorities approved Shenzhen Hepalink Pharmaceutical's  sale of its ivenoxin injection, according to a Thursday filing with the Hong Kong bourse.Ivenoxin is indicated to prevent thrombosis before and after surgery. It also helps with reducing thrombosis risk in patients with acute conditions causing movement restrictions and in hemodialysis patients.The drug also treats deep vein thrombosis and reduces complications in unstable angina, the filing stated.Subsidiary Shenzhen Techdow Medicine produces the injection.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0070":"员工持股","BK1191":"制药","BK0188":"融资融券","09989":"海普瑞","002399":"海普瑞","BK0239":"医药制造"},"translate_title":"海普瑞制药血栓药物获南非上市批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002399":0.9,"09989":1},"content_text":"South African authorities approved Shenzhen Hepalink Pharmaceutical's (HKG:9989, SHE:002399) sale of its ivenoxin injection, according to a Thursday filing with the Hong Kong bourse.Ivenoxin is indicated to prevent thrombosis before and after surgery. It also helps with reducing thrombosis risk in patients with acute conditions causing movement restrictions and in hemodialysis patients.The drug also treats deep vein thrombosis and reduces complications in unstable angina, the filing stated.Subsidiary Shenzhen Techdow Medicine produces the injection.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}